On September 9, INSILICO rose 6% in regular trading, trading at 52.75 HKD/share, with turnover of 179 million HKD, extending momentum from the prior session's strong gains.

On the news front, the company announced that its core pipeline drug Rentosertib's latest research was published in the top-tier journal Nature Biotechnology, demonstrating significant anti-aging potential. This follows the company's September 7 announcement of a strategic cooperation agreement with Mozhuo Bio, under which the two parties will collaborate on high-quality, AI-ready single-cell multi-omics data, feeding into INSILICO's Pharma.AI platform to support training and model iteration for PandaOmics and its virtual senescent cell platform. Citi maintained its Buy rating with an 85 HKD target price, designating it as the top pick in the AI drug discovery sector.

The catalysts build on a strong fundamental backdrop. The company reported 106 million USD in first-half revenue, a 287.2% year-over-year surge, with adjusted net profit of 51.23 million USD, achieving a turnaround from losses. The company also completed a 305 million USD zero-coupon convertible bond issuance in early September, bolstering its cash position to support pipeline advancement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)